RHAPSIDO (Remibrutinib) Patent Expiration, LOE Window & CMS Spending
RHAPSIDO (Remibrutinib) by Novartis: FDA Orange Book core substance LOE 2034-11-13 (last listed 2043-01-19), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $4,521 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N218436 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-11-13 |
| Last Listed Patent or Exclusivity Date | 2043-01-19 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($4,521 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.